1.IN VIVO AND IN VITRO STUDIES ON THE INHIBITION OF TESTICULAR FUNCTION BY GnRH-A IN MALE RATS
Chinese Journal of Endocrinology and Metabolism 1985;0(01):-
The results showed that long-term and non-pulsatile administration of high doses of GnRH-A made in China produced a reversible inhibition of testicular endocrine function in male rats, resulting in decrease of testosterone level and increase of progesterone level both in sera and culture media. Besides, there was a marked decrease in the weight of their seminal vesicles and ventral prostates. It was found that GnRH-A we used had no effect on testis weight, the structure of seminiferous tubules and the production of estrogen by cultured Sertoli cells, and no serious side effect, either. It suggested that home made GnRH-A may be useful in the treatment of sex hormone-dependent diseases as reported in foreign literature.
2.Pathologic staining method improvement for detection of pulmonary cryptococcal disease
Xiuqin WENG ; Shijuan YANG ; Zhisheng XIANG ; Gang CHEN
Cancer Research and Clinic 2017;29(12):841-843
Objective To investigate the pathological staining method of pulmonary cryptococcal disease. Methods Traditional hexamine silver staining and acidified potassium permanganate solution hexamine silver stained were used to analyze paraffin sections of 51 patients with pulmonary cryptococcal disease. Results Compared with traditional hexamine silver stained, the result of acidified potassium permanganate solution with hexamine silver stained was positive, and the whole process only required 25 minutes with the clear background and cryptococcal cyst capsule structure. Conclusion Compared with the traditional hexamine silver staining, acidification of potassium permanganate solution hexamine silver staining method is simpler,easier,more effective and worthy of wide application.
3.Progress of tic disorders based on EEG data analysis
Yuxin XIANG ; Dan SUN ; Zhisheng LIU
International Journal of Pediatrics 2024;51(10):674-679
Tic disorders(TD)are common neurodevelopmental disorders whose pathogenesis is unknown.As a non-invasive examination,electroencephalography(EEG)is widely used in the diagnosis of TD.Due to the high temporal resolution of the EEG signal,when combined with standardized analysis techniques,it can not only be used to understand the physiological functions of the subject,but also to reflect the pathophysiological changes of the disease.Based on the data analysis technology of EEG,this paper reviews the progress of brain connectivity and brain network analysis,time-frequency analysis,and EEG complexity of TD,summarizes the shortcomings of existing research,and provides new ideas for further in-depth study of its pathophysiological mechanism.
4.Interpretation of expert clinicians′ consensus-based definition for treatment failure in chronic tic disorders
Yuxin XIANG ; Dan SUN ; Zhisheng LIU
Chinese Journal of Applied Clinical Pediatrics 2024;39(9):650-654
Correctly identifying the treatment failure in chronic tic disorders can prevent the continued use of unnecessary treatments and facilitate timely escalation to experimental or even invasive treatment.However, there is still a lack of a standard definition for the treatment failure in chronic tic disorders.Led by Professor Davide Martino from the University of Calgary in Canada, several rounds of web-based Delphi surveys were conducted to formulate expert clinicians′ consensus-based definition for treatment failure in chronic tic disorders.This consensus defines the treatment failure in chronic tic disorders from 4 aspects of behavioral and pharmacological interventions: lack of efficacy, adherence, tolerability and behavioral disorders.In addition, it further defines the failure of behavioral intervention as a whole and pharmacological intervention as a whole.This article interprets the process and key contents of the consensus, and discusses the definition of refractory tic disorders to help clinicians improve their understanding of the treatment failure in chronic tic disorders.
5.Epidemic Characteristics and Survival Trends of Upper Gastrointestinal Cancer in Fujian Cancer Registration Areas from 2011 to 2020
Yongying HUANG ; Zhisheng XIANG ; Jingyu MA ; Yongtian LIN ; Yeying WEN ; Yan ZHOU
China Cancer 2024;33(11):886-893
[Purpose]To analyze the epidemic characteristics and survival trends of upper gas-trointestinal cancer in Fujian cancer registration areas from 2011 to 2020.[Methods]Cancer regi-stration data in Fujian Province was collected to calculate the crude incidence and mortality rate,age-standardized incidence/mortality rates by Chinese standard population(ASIRC,ASMRC)and by world standard population(ASIRW,ASMRW)and cumulative rate of 0~74 years old of upper gastrointestinal cancer(including esophageal and gastric cancers)as well as the corresponding temporal trends from 2011 to 2020.Using the Joinpoint software to calculate the annual percent-age change(APC)and average annual percentage change(AAPC)to analyze the trends.The data were divided into two time periods(2011-2015 and 2016-2020)to compare the 5-year relative survival rates of upper gastrointestinal cancer.[Results]From 2011 to 2020,there were 26 286 new cases of upper gastrointestinal cancer in Fujian cancer registration areas,accounting for 20.28%of all malignant tumors.The incidence rate,ASIRC and ASIRW of upper gastrointestinal cancer was 56.52/105,42.55/105,and 42.75/105,respectively,and the cumulative incidence rate(0~74 years old)was 5.32%.Incidence of upper gastrointestinal cancer was higher in men than that in women.The incidence of upper gastrointestinal cancer showed an decreasing trend from 2011 to 2020,with an AAPC of ASIRC of-4.7%(95%CI:-6.6%~-2.9%).There were 11 680 new cases of esophageal cancer in Fujian cancer registration areas,the crude incidence,ASIRC,ASIRW and cumulative incidence(0~74 years old)of esophageal cancer were 25.12/105,18.67/105,18.97/105,and 2.32%,respectively.There were 14 606 gastric cancer new cases in Fujian cancer registration areas during 2011-2020,the crude mortality,ASMRC,ASIRW and cumulative mortality(0~74 years old)of gastric cancer were 31.41/105,23.88/105,23.78/105,and 3.00%,respectively.There were 20 133 upper gastrointestinal cancer deaths during 2011-2020 in Fujian cancer registration areas,accounting for 26.05%of all cancer deaths.The crude mortality,ASMRC and ASMRW of upper gastrointestinal cancer was 43.29/105,31.95/105,and 31.89/105,respectively,the cumu-lative mortality rate(0~74 years old)was 3.84%.The mortality of upper gastrointestinal cancer was higher in men than that in women.The mortality rate of upper gastrointestinal cancer showed a trend of first increase and then decrease,with an APC of 3.5%(95%CI:-0.5%~11.3%)from 2011 to 2014 and-5.2%(95%CI:-8.4%~3.7%)from 2014 to 2020.There were 9 643 deaths of esophageal cancer during 2011-2020 in Fujian cancer registration areas.The crude mortality,ASMRC,ASMRW and cumulative mortality rate(0~74 years old)of esophageal cancer was 20.74/105,15.20/105,15.35/105,and 1.83%,respectively.There were 10 490 deaths of gastric cancer dur-ing 2011-2020 in Fujian cancer registration areas.The crude mortality,ASMRC,ASMRW and cumulative mortality rate(0~74 years old)of gastric cancer was 22.56/105,16.75/105,16.54/105,and 2.00%,respectively.The 5-year relative survival rate for upper gastrointestinal cancer patients during 2011-2015 and 2016-2020 were 24.74%(95%CI:23.92%~25.56%)and 25.49%(95%CI:24.65%~26.34%),respectively.The 5-year relative survival rate for esophageal cancer patients during 2011-2015 and 2016-2020 were 17.15%(95%CI:16.10%~18.22%)and 18.72%(95%CI:17.59%~19.88%),respectively.The 5-year relative survival rate for gastric cancer patients during 2011-2015 and 2016-2020 were 30.90%(95%CI:29.71%~32.10%)and 30.76%(95%CI:29.56%~31.97%),respectively.There was a decreasing trend in 5-year survival of upper gastroin-testinal patients with increasing age,with lower survival rate in patients over 65 years old.[Con-clusion]The incidence and mortality of upper gastrointestinal cancer in Fujian cancer registration areas showed an overall decreasing trend,and the 5-year relative survival rate improved slightly,while the disease burden of upper gastrointestinal cancer remains heavy.Incidence and mortality of upper gastrointestinal cancer of men were higher than those of women,and the elderly patients with upper gastrointestinal cancer had a poorer prognosis.Fujian should pay close attention to the prevention and control of gastric cancer among key groups,and strengthen its comprehensive pre-vention and control ability of upper gastrointestinal cancer.
6.Trend of Incidence and Mortality of Gastric Cancer in Changle District,Fuzhou City of Fujian Province from 1991 to 2020
Ying CHEN ; Jingyu MA ; Zhisheng XIANG ; Yanjian LI ; Jianshun CHEN
China Cancer 2024;33(11):894-900
[Purpose]To analyze the trends of incidence and mortality of gastric cancer in Changle District of Fuzhou City,Fujian Province during 1991-2020.[Methods]The incidence and mor-tality data of gastric cancer from 1991 to 2020 were collected from cancer registries in Changle District.The crude incidence/mortality rates and age-standardized incidence/mortality rates by Chi-nese standard population(ASIRC/ASMRC)of gastric cancer were calculated.The change trends of gastric cancer incidence and mortality were analyzed by the Joinpoint linear regression model,and the annual percentage change(APC)and the average annual percentage change(AAPC)were cal-culated.[Results]From 1991 to 2020,the crude incidence of gastric cancer in Changle District was 62.28/105,the ASIRC was 55.71/105,the ASIRC decreased from 100.94/105 in 1991 to 26.45/105 in 2020 with an AAPC of-4.34%(P<0.01).The crude mortality rate of gastric cancer was 50.58/105,the ASMRC was 44.35/105,the ASMRC decreased from 93.07/105 in 1991 to 20.03/105 in 2020 with an AAPC of-4.71%(P<0.01).From 1991 to 2020,the incidence of gastric cancer in Changle District decreased in age groups of 0~44,45~54,55~64,65~74 and older than 75 years old,with the most significant decrease in the 45~54 age group.The mortality decreased in age group of 0~44,45~54,55~64 and 65~74 with the most significant decrease in 45~54 age group;there was no significant change in 75 and above age group.From 1991 to 2020,the median age of gastric cancer onset and death was delayed by 7 years and 13 years,respectively.[Conclusion]The incidence and mortality of gastric cancer had been considerably decreased during 1991-2000,indicating the success of prevention and control in Changle District;but they are still at a high level,so further targeted prevention and control measures are needed.
7.Incidence and mortality of corpus uteri cancer in China, 2015
Jingyu MA ; Yan ZHOU ; Yongtian LIN ; Zhisheng XIANG ; Rongshou ZHENG ; Siwei ZHANG ; Shaoming WANG ; Ru CHEN ; Wenqiang WEI ; Jie HE
Chinese Journal of Oncology 2021;43(1):108-112
Objective:To estimate the incidence and mortality of corpus uteri cancer in China, 2015.Methods:Quality audit and evaluation of the data from 2015 cancer registration reported by 501 cancer registries were conducted, and 368 cancer registries were included in the analysis. The incidence rate and mortality rate of corpus uteri cancer were calculated according to the factors of the region (urban, rural, east, central, western), sex and age groups. The incidence and mortality of corpus uteri cancer with the 2015 population were estimated. Chinese standard population in 2000 and world Segi′s population were used for the calculation of age-standardized rates (ASR) of incidence and mortality.Results:In 2015, 368 cancer registries included in the analysis covered a total of 309 553 499 populations in China, accounting for 22.52% of the national population. It is estimated that there were about 68 900 new cases of corpus uteri cancer in 2015, the incidence rate was 10.28/10 5, age-standardized incidence rates by Chinese standard population (ASR China) and world standard population (ASR world) were 6.86/10 5 and 6.66/10 5, respectively. The incidence rate of urban area (11.35/10 5) was higher than that of rural area (8.90/10 5), and the incidence of eastern region (12.12/10 5) was higher than the central region (9.94/10 5) and the western region (8.25/10 5). It is estimated that in 2015, there were about 16 000 deaths of corpus uteri cancer, the mortality rate was 2.39/10 5, ASR China was 1.49/10 5, ASR world was 1.47/10 5. The mortality in urban areas (2.40/10 5) is close to rural areas (2.39/10 5); the mortality in central areas (2.55/10 5) was higher than the eastern areas (2.32/10 5) and the western areas (2.31/10 5). Conclusions:In China, the incidence of corpus uteri cancer is on the rise and has a trend of youth, the burden of disease is gradually increasing, which threatens the health of women. Targeted prevention and control measures should be carried out in the different regions.
8.Incidence and mortality of corpus uteri cancer in China, 2015
Jingyu MA ; Yan ZHOU ; Yongtian LIN ; Zhisheng XIANG ; Rongshou ZHENG ; Siwei ZHANG ; Shaoming WANG ; Ru CHEN ; Wenqiang WEI ; Jie HE
Chinese Journal of Oncology 2021;43(1):108-112
Objective:To estimate the incidence and mortality of corpus uteri cancer in China, 2015.Methods:Quality audit and evaluation of the data from 2015 cancer registration reported by 501 cancer registries were conducted, and 368 cancer registries were included in the analysis. The incidence rate and mortality rate of corpus uteri cancer were calculated according to the factors of the region (urban, rural, east, central, western), sex and age groups. The incidence and mortality of corpus uteri cancer with the 2015 population were estimated. Chinese standard population in 2000 and world Segi′s population were used for the calculation of age-standardized rates (ASR) of incidence and mortality.Results:In 2015, 368 cancer registries included in the analysis covered a total of 309 553 499 populations in China, accounting for 22.52% of the national population. It is estimated that there were about 68 900 new cases of corpus uteri cancer in 2015, the incidence rate was 10.28/10 5, age-standardized incidence rates by Chinese standard population (ASR China) and world standard population (ASR world) were 6.86/10 5 and 6.66/10 5, respectively. The incidence rate of urban area (11.35/10 5) was higher than that of rural area (8.90/10 5), and the incidence of eastern region (12.12/10 5) was higher than the central region (9.94/10 5) and the western region (8.25/10 5). It is estimated that in 2015, there were about 16 000 deaths of corpus uteri cancer, the mortality rate was 2.39/10 5, ASR China was 1.49/10 5, ASR world was 1.47/10 5. The mortality in urban areas (2.40/10 5) is close to rural areas (2.39/10 5); the mortality in central areas (2.55/10 5) was higher than the eastern areas (2.32/10 5) and the western areas (2.31/10 5). Conclusions:In China, the incidence of corpus uteri cancer is on the rise and has a trend of youth, the burden of disease is gradually increasing, which threatens the health of women. Targeted prevention and control measures should be carried out in the different regions.
9.Result Analysis of Rural Early Diagnosis and Treatment Program for Upper Gastrointestinal Cancer in Fujian Province from 2013 to 2022
Yongtian LIN ; Jingyu MA ; Zhisheng XIANG ; Yongying HUANG ; Yeying WEN ; Yan ZHOU
China Cancer 2024;33(11):908-914
[Purpose]To analyze the preliminary screening and follow-up results of the early diag-nosis and treatment program for upper gastrointestinal cancer in rural areas of Fujian Province from 2013 to 2022.[Methods]Screening data from the early diagnosis and treatment program for upper gastrointestinal cancer in Fujian Province from 2013 to 2022 were collected and organized.The positive case detection rate,early diagnosis rate,and treatment rate of the screening population were calculated.SPSS 22.0 software was used to test the trend Chi-square test of the annual changes in detection rate,early diagnosis rate and treatment rate.The Chi-square test was used to compare the detection rate and early diagnosis rate between different groups.[Results]From 2013 to 2022,a total of 26 823 screenings and follow-ups were completed in Fujian Province,with de-tection rate,early diagnosis rate,and treatment rate of 1.41%,56.20%,and 92.61%,respec-tively.The early diagnosis rate showed an increasing trend from 2013 to 2022(P<0.05).The initial screening detected rate and early diagnosis rate were 1.38%and 55.59%,respectively,while fol-low-up detection rate and early diagnosis rate were 5.36%and 75.00%.The detection rates for esophagus,cardia,and stomach cases were 0.70%,0.15%,and 0.58%,respectively,with early diagnosis rates of 64.86%,53.66%,and 46.41%,respectively.The differences in detection rates and early diagnosis rates for each site were statistically significant(all P<0.05).[Conclusion]With the development of early diagnosis and treatment of upper gastrointestinal cancer in rural areas of Fujian Province and the improvement of residents'awareness of cancer prevention,the detection rate and early diagnosis rate of upper gastrointestinal cancer in Fujian Province have been im-proved,which plays an important role in improving the survival rate of patients.
10.Expert consensus on the diagnosis, treatment and prevention of monkeypox in children
Rongmeng JIANG ; Yuejie ZHENG ; Lei ZHOU ; Luzhao FENG ; Lin MA ; Baoping XU ; Hongmei XU ; Wei LIU ; Zhengde XIE ; Jikui DENG ; Lijuan XIONG ; Wanjun LUO ; Zhisheng LIU ; Sainan SHU ; Jianshe WANG ; Yi JIANG ; Yunxiao SHANG ; Miao LIU ; Liwei GAO ; Zhuang WEI ; Guanghua LIU ; Gang LIU ; Wei XIANG ; Yuxia CUI ; Gen LU ; Min LU ; Xiaoxia LU ; Runming JIN ; Yan BAI ; Leping YE ; Dongchi ZHAO ; Adong SHEN ; Xiang MA ; Qinghua LU ; Fengxia XUE ; Jianbo SHAO ; Tianyou WANG ; Zhengyan ZHAO ; Xingwang LI ; Yonghong YANG ; Kunling SHEN
Chinese Journal of Applied Clinical Pediatrics 2022;37(13):964-973
Monkeypox is a zoonotic disease.Previous studies have shown that children are vulnerable to monkeypox and are also at high risk for severe disease or complications.In order to improve pediatricians′ understanding of monkeypox and achieve early detection, early diagnosis, early treatment and early disposal, the committee composed of more than 40 experts in the related fields of infectious diseases, pediatrics, infection control and public health formulate this expert consensus, on the basis of the latest clinical management and infection prevention and control for monkeypox released by the World Health Organization (WHO), the guidelines for diagnosis and treatment of monkeypox (version 2022) issued by National Health Commission of the People′s Republic of China and other relevant documents.During the development of this consensus, multidisciplinary experts have repeatedly demonstrated the etiology, epidemiology, transmission, clinical manifestations, laboratory examinations, diagnosis and differential diagnosis, treatment, discharge criteria, prevention, case management process and key points of prevention and control about monkeypox.